Floatz logo

PARAFFINUM FLAVUM

Head and Neck Carcinoma

OHSU Knight Cancer InstitutemixtureN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

37 Active assets in the Head and Neck Carcinoma cohort.

Asset / SponsorPhaseRating
Pembrolizumab
National Cancer Institute (NCI)
Phase 2BB
Tadalafil
University of California, San Diego
Phase 2B
Gdc-0068
National Cancer Institute (NCI)
Phase 2CCC
Binimetinib
National Cancer Institute (NCI)
Phase 2CCC
TRASTUZUMAB
National Cancer Institute (NCI)
Phase 2CCC

View all 43 →

Same molecule, other indications

PARAFFINUM FLAVUM is also rated in:

Radiation-Induced DermatitisDormant
CC
Indicative ·
43 / 100
View asset →
Breast Ductal Carcinoma In SituDormant
CC
Indicative ·
40 / 100
View asset →
Invasive Breast CarcinomaDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →